Bill
A 5062
Requires health insurance and Medicaid coverage for testing and treatments to slow progression of Alzheimer's disease and related disorders.
2026-2027 Regular Session
Introduced by Clinton Calabrese and 13 co-sponsors
NJ health plans must cover FDA-approved Alzheimer’s diagnostic testing and treatments non-step-therapy, aligning with FDA labeling and physician orders.
Passed by the Assembly (78-0-1)